Novo’s investigational obesity and diabetes drug CagriSema reduces ‘food noise’ and shows benefits in organ and bone health – EASD 2026

CagriSema shows strong weight loss and metabolic effects, but commercial impact awaits approval.

What the company is saying

Novo Nordisk is highlighting new phase 3 data for its investigational obesity and diabetes drug CagriSema, presented at the EASD 2026 meeting. The company emphasizes CagriSema’s ability to reduce 'food noise', cravings, and appetite, with a 22.4% body weight reduction versus placebo at 52 weeks. The announcement frames CagriSema as acting on both brain and body, including organ fat and bone health, not just weight and blood sugar. Novo Nordisk stresses the breadth of its clinical program, referencing multiple large-scale phase 3 trials and a global enrolment of 4,600 adults in the REDEFINE program. Martin Holst Lange, executive vice president and chief scientific officer, and Professor Tony Goldstone, a leading academic, are quoted to reinforce the scientific credibility and significance of the findings. The company positions the NDA submission to the US FDA and Health Canada as a major milestone, with a decision expected in Q4 2026.

What the data suggests

The data show CagriSema achieved a 22.4% reduction in body weight versus placebo at 52 weeks in adults with overweight or obesity, with statistical significance (p<0.0001). In type 2 diabetes, CagriSema 2.4 mg/2.4 mg led to a 14.3% body-weight reduction at week 40 and a 14.2% reduction at week 68, alongside significant reductions in abdominal, liver, and pancreatic fat. Bone health markers remained balanced despite weight loss, suggesting no adverse effect on bone maintenance in the short term. The clinical program is extensive, with 4,600 participants in REDEFINE and 2,713 in REIMAGINE 2, supporting the robustness of the findings. The NDA for obesity was submitted in December 2025, and a regulatory decision is expected in Q4 2026. The company employs over 67,000 people worldwide, and the addressable market is large, with 589 million adults living with diabetes globally. The evidence is strong for weight loss and metabolic improvements, but there is no disclosure of financial metrics, commercial projections, or real-world outcomes beyond clinical trial data.

Analysis

The announcement is upbeat, highlighting substantial clinical progress for CagriSema, including statistically significant weight loss and metabolic improvements in multiple phase 3 trials. The narrative is largely supported by specific, realised clinical data (e.g., 22.4% weight reduction at 52 weeks, p<0.0001), and the NDA submission is a concrete milestone. However, the tone inflates the signal by suggesting broad, multi-organ benefits and transformative potential before regulatory approval or commercialisation. Several claims about addressing 'biological drivers' and acting 'well beyond weight reduction' are forward-looking and not yet proven in real-world settings. The capital intensity is high, with large-scale, multi-year trials ongoing and no immediate earnings impact disclosed. While the clinical data is robust, the absence of any financial or commercial metrics means the investment case remains unproven at this stage.

Risk flags

• ●Regulatory approval is pending, with the NDA decision expected in Q4 2026; any delay or negative outcome would materially impact commercial prospects.
• ●All efficacy and safety data are from controlled clinical trials; real-world effectiveness, safety, and adoption rates remain untested at scale.
• ●The announcement does not include any financial projections, pricing strategy, or commercial launch plans, leaving the revenue and profit potential unquantified.
• ●The capital intensity of the program is high, with multiple large-scale, multi-year phase 3 trials ongoing, which could pressure margins if commercial uptake is slower than anticipated.
• ●Broader claims about multi-organ and behavioral benefits are based on early mechanistic and surrogate endpoint data, not on hard clinical outcomes such as cardiovascular events or long-term morbidity.

Bottom line

Novo Nordisk’s CagriSema demonstrates compelling weight loss and metabolic benefits in large phase 3 trials, with a 22.4% reduction in body weight at 52 weeks and significant improvements in organ fat and bone health markers. The NDA for obesity is under review, with a regulatory decision due in Q4 2026, making this the next major catalyst. While the clinical data are robust, the announcement does not address pricing, commercial rollout, or expected financial impact, and all claims of broader health benefits remain tied to surrogate endpoints. Execution risk centers on regulatory approval, real-world safety, and the scale of commercial adoption. Investors should focus on the Q4 2026 regulatory outcome and watch for subsequent updates on launch strategy and early sales. The most important takeaway is that CagriSema’s clinical promise is clear, but its commercial and financial value will only be established after approval and market entry.

Announcement summary

(LSE:0QIU) Novo Nordisk announced new data on its investigational obesity and diabetes drug CagriSema, presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026. In a 52-week functional magnetic resonance imaging (fMRI) study in adults with overweight or obesity, CagriSema modified brain responses to high-calorie food cues in regions linked to cravings, reward, sensory processing, and behavioural control. The study showed that CagriSema substantially improved eating behaviour, reduced ‘food noise’, cravings, hunger, appetite, and food-related thoughts, and improved craving control after both 22 and 52 weeks of treatment. These improvements were associated with a 22.4% reduction in body weight versus placebo at 52 weeks (estimated treatment difference at 52 weeks, p<0.0001). In a diabetes MRI sub-study from the phase 3a REIMAGINE 1 trial, CagriSema 2.4 mg/2.4 mg produced significant reductions in fat in the abdomen and around the liver and pancreas, alongside a 14.3% body-weight reduction at week 40. A post hoc analysis of bone markers in the phase 3 REIMAGINE 2 trial showed signs of healthy balance in bone maintenance with a 14.2% body-weight reduction at week 68 in adults with inadequately controlled type 2 diabetes. Novo Nordisk submitted a New Drug Application (NDA) for CagriSema for obesity to the US FDA and Health Canada in December 2025, with a decision expected in Q4 2026. In 2026, a high-dose CagriSema 2.4 mg/7.2 mg phase 3 trial was initiated in adults with obesity. The REDEFINE phase 3 clinical development programme for obesity includes two pivotal phase 3 trials that enrolled approximately 4,600 adults with overweight or obesity. REDEFINE 1 is a 68-week efficacy and safety phase 3 trial in 3,417 adults with obesity or overweight with one or more comorbidities and without type 2 diabetes. REDEFINE 2 is a 68-week efficacy and safety phase 3 trial in 1,206 adults with type 2 diabetes and either obesity or overweight. REDEFINE 3 is an event-driven cardiovascular outcomes phase 3 trial in 7,000 adults with established cardiovascular disease with or without type 2 diabetes. REDEFINE 8 is a 104-week efficacy and safety phase 3 trial in 400 adults with obesity, including a 52-week extension phase. REDEFINE 9 is a 68-week efficacy and safety phase 3 trial in 300 adults with overweight or obesity. REDEFINE 11 is an 80-week efficacy and safety phase 3 trial in 600 adults with obesity, including an 80-week extension phase. The REIMAGINE phase 3 clinical development programme for type 2 diabetes includes REIMAGINE 1, a 40-week trial in 189 adults with type 2 diabetes inadequately controlled on diet and exercise; REIMAGINE 2, a 68-week trial in 2,713 adults with type 2 diabetes inadequately controlled with metformin with or without an SGLT2 inhibitor; and REIMAGINE 3, a 40-week trial in 274 adults with type 2 diabetes as an add-on to once-daily basal insulin with or without metformin. REIMAGINE 4 and 5 evaluated CagriSema versus tirzepatide in adults with type 2 diabetes on standard of care. Novo Nordisk employs over 67,000 people worldwide. According to the International Diabetes Federation, approximately 589 million adults are living with diabetes globally, the majority with type 2 diabetes.

Disagree with this article?